Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
featured
Do You Take Two Insulins to Treat Your Type 2 Diabetes?

> Metformin Januvia, Onglyza, Tradjenta, or Nesina. (DPP-4’s) Farxiga, Invokana, or Jardiance. (SGLT2’s) Rybelsus (Oral GLP-1) Participants may also be

  • 0 views
  • 26 Feb, 2021
  • 1 location
featured
A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

A long-term 4+ year, double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

  • 270 views
  • 08 Nov, 2020
  • 1 location
DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

This study aims to elucidate the impact of SGLT2 inhibition on peripheral vascular function, renal function, fluid volume, neurohormonal activation and inflammatory/fibrotic pathways in patients

hemoglobin a1c
body mass index
diabetes
systolic blood pressure
type 1 diabetes mellitus
  • 0 views
  • 23 Jan, 2021
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure

insulin resistance or type 2 diabetes mellitus. Empagliflozin is a potent and selective inhibitor of the sodium glucose cotransporter 2 (SGLT2) used in the treatment of type 2 diabetes. By

nesiritide
various combinations
nt-probnp
natriuretic
b-type natriuretic peptide
  • 0 views
  • 26 Jan, 2021
  • 1 location
Dapagliflozin and Hepatic Glucose Metabolism

the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake

  • 0 views
  • 24 Jan, 2021
  • 1 location
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes

A real-world, nationwide, register-based, randomised trial (RRCT) comparing SGLT2 inhibitors with metformin as standard treatment in early typ 2 diabetes. An open-label trial addressing efficacy

sglt2 inhibitor
dapagliflozin
metformin
sglt2
  • 22 views
  • 24 Jan, 2021
  • 1 location
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.

prediabetic state
fasting
metformin
dapagliflozin
impaired glucose tolerance
  • 32 views
  • 25 Jan, 2021
  • 1 location
Effect of Pioglitazone on T2DM Patients With COVID-19

Approximately 10-15% of patients infected with COVID-19 develop severe illness characterized by respiratory distress, increased risk of clotting disease, myocardial damage, stroke and mortality. Subjects with Type 2 diabetes (T2DM) are at increased risk for severe COVID-19 disease. Exuberant inflammatory and immune responses were suggested as the etiology responsible for …

  • 0 views
  • 25 Mar, 2021
  • 5 locations
Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity

A Phase III, single-centre, randomized, 2-arm, parallel-group, double blind, placebo-controlled study, consisting of a screening phase (Days -14 to -1), a 4-week double-blind, placebo-controlled treatment phase and a 4-week follow-up phase. Subjects: Type 2 diabetic patients and coronary artery diseases (CAD) not requiring revascularization or underwent percutaneous coronary intervention (PCI) …

  • 0 views
  • 16 Mar, 2021
  • 1 location
SGLT2 Inhibition in Older Obese Adults With Pre-diabetes

Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration

hemoglobin a1c
body mass index
diabetes
blood sugar
  • 72 views
  • 25 Jan, 2021
  • 1 location